Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops take aim at dry eye: phase 2 trial puts TJO-087 to the test

NCT ID NCT07810972

Symptom relief Sponsor: Taejoon Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing an experimental eye drop called TJO-087 in adults with dry eye syndrome. The trial enrolls about 90 people who have dry eye symptoms and signs of corneal damage. Participants receive either TJO-087 or a placebo drop for 3 months. The main measure is whether corneal staining, a sign of eye surface damage, improves more with TJO-087 than with placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TJO-087, an experimental eye drop for dry eye
What this could lead to
If it works, TJO-087 could become another treatment option for dry eye syndrome, a common condition that can make eyes feel gritty and sore.
What could go wrong
This is a mid-stage trial with 90 people, so it may not show a clear benefit over placebo. Eye drops can cause stinging or irritation, and results in a small group may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

90 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥20 years (male or female) * Patients with dry eye symptoms * Fluorescein corneal staining score(NEI scale) ≥4 * Schirmer test result (without anesthesia) ≤10 mm/5 min in * Tear film break-up time (TBUT) \<10 seconds Exclusion Criteria: * Presence or history of systemic or ocular disorder or condition that could affect the interpretation of study results * Intraocular pressure (IOP) \>21 mmHg * Planned use of contact lenses during the study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye syndrome (DES) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye syndrome (DES)

Contacts and locations

Locations

  • Korea University Guro Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.